41 results about "Skeletal muscle damage" patented technology

Compositions and methods of using cells derived from postpartum tissue such as the umbilical cord and placenta, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed.

The present invention involves the use of a compound that reduces the level of free fatty acids circulating in the plasma of a subject in the manufacture of a medicament for the treatment of prevention of muscle (particularly cardiac or skeletal muscle) impairment or fatigue.

The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an HMG-CoA reductase inhibitor for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixtures thereof, and (3) a swelling agent to form a sustained release composition for extended release of the nicotinic acid or nicotinic acid compound or mixtures thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a composition for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl methylcellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an HMG-CoA reductase inhibitor in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compounds to provoke flushing reactions in individuals.

Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease with umbilical derived cells and fibrin glue are disclosed.

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of rhabdomyolysis and / or elevated CPK as possible side effects; wherein the patients and / or prescribing physicians and other medical care providers are advised to monitor for such conditions and employ methods that will improve the therapeutic outcome in the few patients who experience rhabdomyolysis and / or elevated CPK associated with zonisamide therapy.

The invention relates to a rosuvastatin calcium sustained-release preparation and a preparation method thereof. The rosuvastatin calcium sustained-release preparation basically contains 5 to 10mg of rosuvastatin calcium, and the balance of sustained-release framework material and other pharmaceutical excipients. The preparation method is simple; and all the materials are proportioned and the preparation is prepared by the preparation method for common tablets, granules or capsules. The rosuvastatin calcium sustained-release preparation prepared by the method avoids adverse reactions such as rhabdomyolysis, proteinuria, nephrosis, kidney failure, hepatotoxicity and the like caused by overdosage of medicaments; meanwhile, due blood concentration and time for treating diseases after the medicaments are taken can be maintained, and the peak valley phenomenon of the blood concentration is effectively avoided.

The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of statin-induced muscle toxicity.

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of rhabdomyolysis and / or elevated CPK as possible side effects; wherein the patients and / or prescribing physicians and other medical care providers are advised to monitor for such conditions and employ methods that will improve the therapeutic outcome in the few patients who experience rhabdomyolysis and / or elevated CPK associated with zonisamide therapy.

The invention discloses a method for preparing a bionic skeletal muscle composite tissue through multi-channel extrusion 3D biological printing. The preparation method comprises the following steps: preparing bone scaffold bionic bio-ink, periosteum bionic bio-ink, sarcolemma bionic bio-ink and muscle bionic bio-ink; respectively mixing MSCs and C2C12 with the corresponding bionic bio-inks; and printing and forming a bionic bone, bionic periosteum, bionic sarcolemma and bionic muscle four-layer composite tissue engineering scaffold by using a multi-channel extrusion 3D biological printer. Themethod for preparing the bionic skeletal muscle composite tissue through multi-channel extrusion 3D biological printing can minimize fibrosis during traumatic skeletal muscle injury recovery; the bionic skeletal muscle composite tissue prepared through multi-channel extrusion 3D biological printing can replace structures and functions of bones and skeletal muscles at the same time, and supports proliferation and differentiation of myoblasts and osteoblasts; and an implant is easy to customize by utilizing a 3D biological printing technology, so that the implant is suitable for any defect shape.

Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease with umbilical derived cells and fibrin glue are disclosed.

The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.

The invention discloses a peptide juice compounded with anti-fatigue peptide and mango juice and a preparation method thereof, which belongs to the technical field of liquid processing and provides a new type of functional peptide juice food for the market. Kiwi peptide powder, seabuckthorn peptide powder, tiger palm peptide powder, Coprinus comatus peptide powder, golden mushroom peptide powder, bolete peptide powder, beet peptide powder, matsutake peptide powder, brown rice peptide powder, blueberry peptide powder, pea peptide powder , Chestnut mushroom peptide powder. These small molecular peptides can ensure the nutrition needed by athletes, have energy, strength and speed in competitions, reduce skeletal muscle damage, and help win championships. These are the main ingredients. Then take polysaccharides, vitamins, trace elements, essential oils, etc. as auxiliary materials. These main materials and auxiliary materials are weighed, mixed, granulated, dried and packaged to make mixed peptide powder. Take the pure mango juice and put it into the fresh-keeping can. According to the ratio of 1:50. Peptide Juice Made. It has the effect of supplementing nutrition.

Methods and compositions comprising ornithine and / or aspartate that are useful for lowering one or more hyperlipidemic risk factor levels are described. More specifically, compositions comprising ornithine and / or aspartate that are useful for lowering lipid and / or lipoprotein levels, such as triglyceride, cholesterol and LDL levels, in the bloodstream in a subject are described. Methods of using compositions comprising ornithine and / or aspartate for ameliorating the side-effect induced by a therapeutic agent (e.g., statin) or a condition that is associated with an elevation of CPK (e.g., rhabdomyolysis or myopathy) are also described.

The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy, or rhabdomyolysis.

A method of alleviating the symptoms of rhabdomyolysis or the side effects of statin DRUG administration is disclosed. The method comprises the administration of D-ribose in doses of three to ten grams at least twice a day until the symptoms or side effects are alleviated.

The invention relates to the field of forensic medicine, in particular to a skeletal muscle early injury time prediction method based on Stacking ensemble learning, which comprises the following steps: collecting skeletal muscle samples of rats at different injury time, and obtaining skeletal muscle injury repair related gene expression quantity; according to the prediction models of the three base classifiers, stacking the prediction probability values of the three base classifiers to form a new feature set, and conducting training to obtain a final Stacking ensemble learning model; and inputting the data of an unknown sample into the Stacking ensemble learning model so as to predict the damage time of the unknown sample. According to the prediction method, prediction results of the three base classifiers are integrated by adopting Stacking ensemble learning, and the three base classifiers are subjected to parameter optimization through grid search and cross validation, so that the accuracy and stability of skeletal muscle early injury time deduction are effectively improved.

The invention provides aptamers capable of binding to the skeletal Troponin I protein useful as diagnostics of skeletal muscle damage in which the skeletal Troponin I protein has been implicated.

The invention discloses a myoglobin immunoadsorbent which comprises a solid phase carrier and a myoglobin polyclonal antibody coupled with the carrier; the myoglobin polyclonal antibody is a polyclonal antibody obtained by using a compound as an immunogen, wherein the compound is formed by crosslinking keyhole limpet hemocyanin with antigenic peptide; the amino acid sequence of the antigenic peptide is shown in sequence table SEQ ID:No.5. The invention also discloses a myoglobin immunoadsorption column which uses the myoglobin immunoadsorbent as a filler, a myoglobin immunoadsorption device containing the myoglobin immunoadsorption column, and a first aid tool kit. The immunoadsorbent and the device of the invention are established in a convenient blood perfusion treatment mode, can realize myoglobin adsorption with high specificity, and are especially suitable for on-site rescue of rhabdomyolysis. Compared with modes of hemodialysis or hemofiltration, the whole blood perfusion mode has less water and electricity consumption, is easier to realize, and more meets the requirements of disaster accident on-site rescue.

The invention provides application of leucyl-tRNA synthetase 2 to repair after skeletal muscle injury. The skeletal muscle repairing agent has the advantage of effectively promoting skeletal muscle repairing after injury.

The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an HMG-CoA reductase inhibitor for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixtures thereof, and (3) a swelling agent to form a sustained release composition for extended release of the nicotinic acid or nicotinic acid compound or mixtures thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention and by way of example, a composition for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl methylcellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an HMG-CoA reductase inhibitor in immediate release form is disclosed. Also in accordance with the present invention. the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compounds to provoke flushing reactions in individuals.

The invention discloses application of a medicine in preparation of drugs for reducing the muscle toxicity of statins. Experimental results show that a heart-nourishing tablet can reduce statins related skeletal muscle injury and improve exercise capacity by enhancing mitochondrial activity, improving oxidative stress and inhibiting myolysis of ApoE- / -mice fed with high fat in exercise training, and the effect is remarkable.

Disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same.